* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:56:41 ON 24 APR 2008

=> index bioscience medicine

INDEX 'ADISCTL, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:57:02 ON 24 APR 2008

72 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> S ((tetrahydrofolate (w) synthase) or (tetrahydrofolate (w) synthetase))
1 FILE ADISNEWS
19 FILE AGRICOLA
1 FILE AQUASCI
4 FILE BIOENG
77 FILE BIOSIS
5 FILE BIOTECHABS
5 FILE BIOTECHDS
30 FILE BIOTECHNO
7 FILE CABA
140 FILE CAPLUS
2 FILE CEABA-VTB
4 FILE CONFSCI
4 FILE DDFB
4 FILE DDFU
19 FILE DGENE
22 FILE DISSABS
4 FILE DRUGB
7 FILE DRUGU
45 FILE EMBASE
24 FILE ESBIOBASE
1286 FILE GENBANK
5 FILE IFIPAT
35 FILE LIFESCI
48 FILE MEDLINE
1 FILE NTIS
32 FILE PASCAL
93 FILE SCISEARCH
33 FILE TOXCENTER
72 FILE USPATFULL
6 FILE USPAT2
4 FILE WPIDS
68 FILES SEARCHED...
4 FILE WPINDEX

32 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STNINDEX

L1 QUE ((TETRAHYDROFOLATE (W) SYNTHASE) OR (TETRAHYDROFOLATE (W) SYNTHETASE))

=> d rank
F1 1286 GENBANK
F2 140 CAPLUS
F3 93 SCISEARCH
F4 77 BIOSIS
F5 72 USPATFULL
F6 48 MEDLINE
F7 45 EMBASE
F8 35 LIFESCI
F9 33 TOXCENTER

F10 32 PASCAL
F11 30 BIOTECHNO
F12 24 ESBIOBASE
F13 22 DISSABS
F14 19 AGRICOLA
F15 19 DGENE
F16 7 CABA
F17 7 DRUGU
F18 6 USPAT2
F19 5 BIOTECHABS
F20 5 BIOTECHDS
F21 5 IFIPAT
F22 4 BIOENG
F23 4 CONFSCI
F24 4 DDFB
F25 4 DDFU
F26 4 DRUGB
F27 4 WPIDS
F28 4 WPINDEX
F29 2 CEABA-VTB
F30 1 ADISNEWS
F31 1 AQUASCI
F32 1 NTIS

=> file f2-f14,

FILE 'CAPLUS' ENTERED AT 12:58:22 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 12:58:22 ON 24 APR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOSIS' ENTERED AT 12:58:22 ON 24 APR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 12:58:22 ON 24 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:58:22 ON 24 APR 2008

FILE 'EMBASE' ENTERED AT 12:58:22 ON 24 APR 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 12:58:22 ON 24 APR 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'TOXCENTER' ENTERED AT 12:58:22 ON 24 APR 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 12:58:22 ON 24 APR 2008
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 12:58:22 ON 24 APR 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:58:22 ON 24 APR 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DISSABS' ENTERED AT 12:58:22 ON 24 APR 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'AGRICOLA' ENTERED AT 12:58:22 ON 24 APR 2008

=> S L1

```
L2        670 L1

=> S (cancer or carcinoma or tumor or neoplasia) (s) L2
  9 FILES SEARCHED...
L3        35 (CANCER OR CARCINOMA OR TUMOR OR NEOPLASIA) (S) L2

=> S (colon or colorectal) and L3
L4        27 (COLON OR COLORECTAL) AND L3

=> S express? and L4
L5        25 EXPRESS? AND L4

=> S (detect? or diagnos?) and L5
  11 FILES SEARCHED...
L6        23 (DETECT? OR DIAGNOS?) AND L5

=> S human and L6
L7        23 HUMAN AND L6

=> dup rem L7
PROCESSING COMPLETED FOR L7
L8        23 DUP REM L7 (0 DUPLICATES REMOVED)

=> d ibib abs L8 1-23

L8   ANSWER 1 OF 23  USPATFULL on STN
ACCESSION NUMBER:      2007:256701  USPATFULL <<LOGINID::20080424>>
TITLE:                 Ocular fluid markers
INVENTOR(S):           Liotta, Lance A., Bethesda, MD, UNITED STATES
                       Zhou, Weidong, Manassas, VA, UNITED STATES
                       Espina, Virginia, Rockville, MD, UNITED STATES
                       Petricoin, Emanuel, Gainesville, VA, UNITED STATES

                           NUMBER      KIND    DATE
                           ----------- ------ --------
PATENT INFORMATION:    US 20072246 44      A1   20070927
APPLICATION INFO.:     US 2007-698998      A1   20070129 (11)

                           NUMBER      DATE
                           ----------- --------
PRIORITY INFORMATION:  US 2006-762499P     20060127 (60)
DOCUMENT TYPE:         Utility
FILE SEGMENT:          APPLICATION
LEGAL REPRESENTATIVE:  MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON
                       BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
NUMBER OF CLAIMS:      34
EXEMPLARY CLAIM:       1
NUMBER OF DRAWINGS:    2 Drawing Page(s)
LINE COUNT:            11394
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to the analysis and monitoring of ocular
       fluids for determining the physiological state of an organism, to
       monitor drug efficacy and dynamics, for early disease  ***detection***
       , as well as to certain molecular markers and fingerprints of identified
       molecules or molecule fragments in such analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8   ANSWER 2 OF 23  USPATFULL on STN
ACCESSION NUMBER:      2007:231807  USPATFULL <<LOGINID::20080424>>
TITLE:                 Methods Of Regulating Metabolism And Mitochondrial
                       Function
INVENTOR(S):           Mootha, Vamsi Krishna, Brookline, MA, UNITED STATES
                       Altshuler, David, Brookline, MA, UNITED STATES

                           NUMBER      KIND    DATE
                           ----------- ------ --------
PATENT INFORMATION:    US 2007203083       A1   20070830
APPLICATION INFO.:     US 2004-560501      A1   20040614 (10)
                       WO 2004-US19017     20040614
```

20060615 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-478238P	20030613 (60)
	US 2003-525548P	20031126 (60)
	US 2004-559141P	20040402 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 18400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel methods of regulating metabolism and mitochondrial biogenesis. Some aspects of the invention relate to methods of treating or preventing diseases in a patient associated with reduced mitochondrial function, to methods of identifying agents to treat such diseases, and to methods of ***diagnosing*** such diseases. Other aspects of the invention relate to a set of coordinately-regulated genes which regulate oxidative phosphorylation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:142095 USPATFULL <<LOGINID::20080424>>
TITLE: Molecular nephrotoxicology modeling
INVENTOR(S): Mendrick, Donna L., Gaithersburg, MD, UNITED STATES
Porter, Mark W., Gaithersburg, MD, UNITED STATES
Johnson, Kory R., Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007124086	A1	20070531
APPLICATION INFO.:	US 2006-642647	A1	20061221 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-301856, filed on 22 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-152319, filed on 22 May 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)
	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)
	US 2001-303807P	20010710 (60)
	US 2001-303808P	20010710 (60)
	US 2001-315047P	20010828 (60)
	US 2001-324928P	20010927 (60)
	US 2001-330867P	20011101 (60)
	US 2001-330462P	20011022 (60)
	US 2001-331805P	20011121 (60)
	US 2001-336144P	20011206 (60)
	US 2001-340873P	20011219 (60)
	US 2002-357843P	20020221 (60)
	US 2002-357842P	20020221 (60)
	US 2002-357844P	20020221 (60)
	US 2002-364134P	20020315 (60)
	US 2002-370206P	20020408 (60)
	US 2002-370247P	20020408 (60)
	US 2002-370144P	20020408 (60)
	US 2002-371679P	20020412 (60)
	US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: COOLEY GODWARD KRONISH LLP, ATTN: Patent Group, Suite 500, 1200 - 19th Street, NW, WASHINGTON, DC, 20036-2402, US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 15391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the elucidation of the global changes in gene ***expression*** and the identification of toxicity markers in kidney tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential ***expression*** that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:107995 USPATFULL <<LOGINID::20080424>>
TITLE: Molecular nephrotoxicology modeling
INVENTOR(S): Mendrick, Donna L., Gaithersburg, MD, UNITED STATES
Porter, Mark W., Gaithersburg, MD, UNITED STATES
Johnson, Kory R., Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007093969	A1	20070426
APPLICATION INFO.:	US 2003-515325	A1	20031124 (10)
	WO 2003-US37556		20031124
			20050916 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-10301856	20021122

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: COOLEY GODWARD LLP, THE BROWN BUILDING - 875 15TH STREET, NW, SUITE 800, WASHINGTON, DC, 20005-2221, US
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
LINE COUNT: 16092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the elucidation of the global changes in gene ***expression*** and the identification of toxicity markers in kidney tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential ***expression*** that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2007:42463 USPATFULL <<LOGINID::20080424>>
TITLE: Tetrahydrofolate synthetase gene
INVENTOR(S): Sugiura, Takeyuki, Edogawa-ku, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007037159	A1	20070215
APPLICATION INFO.:	US 2004-573969	A1	20040930 (10)
	WO 2004-JP14812		20040930
			20060330 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-341245	20030930

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB By finding a novel ***tetrahydrofolate*** ***synthetase*** gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of ***colon*** ***cancer*** are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging ***colon*** ***cancer*** , characterizing in that ***expressed*** amount of said DNA is measured; a kit for judging ***colon*** ***cancer*** ; a preventive agent and/or therapeutic agent for ***colon*** ***cancer*** .

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:300591 CAPLUS <<LOGINID::20080424>>
DOCUMENT NUMBER: 142:368776
TITLE: Mitochondrial C1-tetrahydrofolate synthetase upregulated in ***human*** ***colon*** adenocarcinoma: cDNA cloning and ***diagnostic*** or therapeutic uses
INVENTOR(S): Sugiura, Takeyuki
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030953	A1	20050407	WO 2004-JP14812	20040930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20070037159	A1	20070215	US 2006-573969	20060330
PRIORITY APPLN. INFO:			JP 2003-341245	A 20030930
			WO 2004-JP14812	W 20040930

AB Thus provides a novel tetrahydrofolate synthase gene, a protein encoded by this gene, recombinant ***expression*** of the protein, and probes/primers for the gene. Also provided are a method of screening a compd. inhibiting the cell growth promoting activity of the protein; a method and kit for ***diagnosing*** ***colon*** cancer by measuring the ***expression*** level of the gene; a method of preventing or treating ***colon*** cancer; and use as preventive and/or therapeutic agent for ***colon*** cancer. To seek the genes

involved in the development of ***colorectal*** cancer, the authors analyzed the microarray gene ***expression*** profiles of ***human*** normal and cancerous ***colon*** tissues using the BioExpress database platform. Through the anal. the authors found one gene named DKFZp586G1517 that was upregulated in ***colon*** adenocarcinomas. The full-length cDNA of the DKFZp586G1517 cloned by polymerase chain reaction (PCR) encodes a protein with 978 amino acids, which is homologous to the ***human*** cytosolic C1-tetrahydrofolate synthetase and contains a mitochondrial target signal at N-terminus. The gene product ***expressed*** in 293 cells was localized in mitochondria and processed at the predicted signal cleavage site, supporting the idea that DKFZp586G1517 is a novel mitochondrial C1-tetrahydrofolate synthetase (mtC1-THFS). The overexpression of mtC1-THFS in 293 cells stimulated the colony formation. These results suggest that mtC1-THFS may participate in the progression of ***colorectal*** cancer by conferring growth advantage and could be a new mol. target for cancer therapy.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:50706 USPATFULL <<LOGINID::20080424>>
TITLE: Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis
INVENTOR(S): Campbell, David Alan, San Diego, CA, UNITED STATES
Liyanage, Marek, Carlsbad, CA, UNITED STATES
Szardenings, Anna Katrin, San Diego, CA, UNITED STATES
Wu, Min, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): ActivX Biosciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005043507	A1	20050224
APPLICATION INFO.:	US 2004-817454	A1	20040401 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459797P	20030401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides tagged acyl phosphate probes ("TAPPs"), and methods of their preparation and use. The subject methods and compositions can provide enhanced simplicity and accuracy in identifying changes in the presence, amount, or activity of target proteins in a complex protein mixture, preferably nucleotide binding proteins using nucleotide binding protein-directed TAPPs. The profiling methods described herein can have a number of steps leading to the identification of target nucleotide binding protein(s) in a complex protein mixture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:633950 CAPLUS <<LOGINID::20080424>>
DOCUMENT NUMBER: 141:169975
TITLE: Purification, cloning and characterization of L-amino acid oxidase with cytotoxic activity from Aplysia punctata and use for the ***diagnosis*** and treatment of cancer
INVENTOR(S): Butzke, Daniel; Goedert, Sigrid; Dittrich, Michael; Rudel, Thomas; Meyer, Thomas F.
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., Germany

SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065415	A2	20040805	WO 2004-EP423	20040120
WO 2004065415	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
EP 1585761	A2	20051019	EP 2004-703388	20040120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060165698	A1	20060727	US 2005-542769	20050720

PRIORITY APPLN. INFO.: EP 2003-1232 A 20030120
EP 2003-26613 A 20031119
WO 2004-EP423 W 20040120

AB The present invention relates to a cytotoxic polypeptide which is an L-amino acid oxidase isolated from the ink of the sea hare Aplysia punctata via anion exchange chromatog. and gel filtration. The polypeptide is termed APIT (Aplysia punctata ink toxin). Tumor cells treated with APIT displays a morphol. which is neither typical for apoptosis nor for necrosis but rather is typical for oxidative damage induced cell death. The cDNA sequence and the encoded amino acid sequence of APIT isoforms are provided. The toxic and enzymic activity of APIT is due to the presence of an attached FAD. It was demonstrated that the cytotoxic activity depended on the H2O2 producing enzymic activity of APIT. From all amino acids tested only L-lysine and L-arginine served as substrates for APIT to produce hydrogen peroxide. Sensitivity of different tumor cell lines to APIT induced cell death was studied. Change in protein ***expression*** pattern in Jurkat T cells after treatment with APIT was investigated. The influence of APIT on the gene exression of tumor cells was investigated by Microarray technol. It was shown that healthy ***human*** cells are resistant against the APIT-induced cell death. APIT can be used for the manuf. of a medicament for the ***diagnosis*** and treatment of cancer.

L8 ANSWER 9 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:133338 USPATFULL <<LOGINID::20080424>>
TITLE: Targets for therapeutic intervention identified in the mitochondrial proteome
INVENTOR(S): Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Fahy, Eoin D., San Diego, CA, UNITED STATES
Zhang, Bing, Spring, TX, UNITED STATES
Gibson, Bradford W., Berkeley, CA, UNITED STATES
Taylor, Steven W., San Diego, CA, UNITED STATES
Glenn, Gary M., Encinitas, CA, UNITED STATES
Warnock, Dale E., San Diego, CA, UNITED STATES
Gaucher, Sara P., Castro Valley, CA, UNITED STATES
PATENT ASSIGNEE(S): MitoKor Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
The Buck Institute for Age Research, Novato, CA, UNITED STATES, 94948-0638 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101874	A1	20040527
APPLICATION INFO.:	US 2003-408765	A1	20030404 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-412418P	20020920 (60)
	US 2002-389987P	20020617 (60)
	US 2002-372843P	20020412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5998
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mitochondrial targets for drug screening assays and for therapeutic intervention in the treatment of diseases associated with altered mitochondrial function are provided. Complete amino acid sequences [SEQ ID NOS:1-3025] of polypeptides that comprise the ***human*** heart mitochondrial proteome are provided, using fractionated proteins derived from highly purified mitochondrial preparations, to identify previously unrecognized mitochondrial molecular components.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:82668 USPATFULL <<LOGINID::20080424>>
TITLE: Analysis and modification of gene ***expression*** in marine invertebrate cells
INVENTOR(S): Willoughby, Robin, Vero Beach, FL, UNITED STATES
Pomponi, Shirley A., Fort Pierce, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040063119	A1	20040401
	US 7135292	B2	20061114
APPLICATION INFO.:	US 2003-611113	A1	20030630 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-392626P	20020628 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention identifies changes in gene ***expression*** related to treatment of marine invertabret cell cultures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:7326 USPATFULL <<LOGINID::20080424>>
TITLE: Markers of neuronal differentiation and morphogenesis
INVENTOR(S): Loring, Jeanne F., Foster City, CA, UNITED STATES
Kaser, Mathew R., Castro Valley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005559	A1	20040108
APPLICATION INFO.:	US 2002-62674	A1	20020130 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-625102, filed on 24 Jul 2000, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 5725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides cDNAs that are ***diagnostic*** of and

participate in neuronal differentiation and morphogenesis, proteins encoded by the cDNAs and agonists, antagonists, and antibodies that specifically bind the protein. The invention also provides compositions containg cDNAs, proteins, or antibodies and methods for their use ***diagnostically*** and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:301902 USPATFULL <<LOGINID::20080424>>
TITLE: Methods for inhibition of membrane fusion-associated events, including HIV transmission
INVENTOR(S): Bolognesi, Dani Paul, Durham, NC, United States
Matthews, Thomas James, Durham, NC, United States
Wild, Carl T., Durham, NC, United States
PATENT ASSIGNEE(S): Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6824783	B1	20041130
APPLICATION INFO.:	US 1995-487266		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, now patented, Pat. No. US 6479055
Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, now patented, Pat. No. US 6017536
Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994, now patented, Pat. No. US 5440656
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Housel, James
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 118
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 25013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of ***human*** and non- ***human*** retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 23 Elsevier BIOBASE COPYRIGHT 2008 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2004038789 ESBIOBASE <<LOGINID::20080424>>
TITLE: A novel mitochondrial C.sub.1-tetrahydrofolate synthetase is upregulated in ***human*** ***colon*** adenocarcinoma
AUTHOR: Sugiura T.; Nagano Y.; Inoue T.; Hirotani K.
CORPORATE SOURCE: T. Sugiura, Discovery Research Laboratory, Tokyo R and D Center, Daiichi Pharmaceutical Co. Ltd., 16-13, Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. E-mail: sugiuy796@daiichipharm.co.jp
SOURCE: Biochemical and Biophysical Research Communications, (27 FEB 2004), 315/1 (204-211), 27 reference(s)
CODEN: BBRCA0 ISSN: 0006-291X
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AB To seek the genes involved in the development of ***colorectal*** ***cancer*** , we analyzed the microarray gene ***expression***

profiles of ***human*** normal and cancerous ***colon*** tissues using the BioExpress database platform. Through the analysis we found one gene named DKFZp586G1517 that was upregulated in ***colon*** adenocarcinomas. The full-length cDNA of the DKFZp586G1517 cloned by polymerase chain reaction (PCR) encodes a protein with 978 amino acids, which is homologous to the ***human*** cytosolic C.sub.1- ***tetrahydrofolate*** ***synthetase*** and contains a mitochondrial target signal at N-terminus. The gene product ***expressed*** in 293 cells was localized in mitochondria and processed at the predicted signal cleavage site, supporting the idea that DKFZp586G1517 is a novel mitochondrial C.sub.1- ***tetrahydrofolate*** ***synthetase*** (mC.sub.1-THFS). The overexpression of mC.sub.1-THFS in 293 cells stimulated the colony formation. These results suggest that mC .sub.1-THFS may participate in the progression of ***colorectal*** ***cancer*** by conferring growth advantage and could be a new molecular target for ***cancer*** therapy. .COPYRGT. 2004 Elsevier Inc. All rights reserved.

ACCESSION NUMBER: 2003:40533 USPATFULL <<LOGINID::20080424>>
TITLE: Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6518013	B1	20030211
APPLICATION INFO.:	US 1995-485546		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, now patented, Pat. No. US 6017536
Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP, Nelson, M. Bud
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 24700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the ***human*** immunodeficiency virus type 1(HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that ***detects*** related structural motifs (e.g., ALLMOTI 5, 107.times.178.times.4, and PLZIP) in other viral proteins was employed to identify similar regions in the Epstein-Barr virus (EBV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the EBV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of EBV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of EBV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2002:297296 USPATFULL <<LOGINID::20080424>>
TITLE: Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
INVENTOR(S): Bolognesi, Dani Paul, Durham, NC, United States
Matthews, Thomas James, Durham, NC, United States
Wild, Carl T., Durham, NC, United States
Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
Langlois, Alphonse J., Durham, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479055	B1	20021112
APPLICATION INFO.:	US 1995-470896		19950606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, now patented, Pat. No. US 6017536 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 26553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus ("RSV") transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1.sub.LAI transmembrane protein (TM) gp41.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2001:67794 USPATFULL <<LOGINID::20080424>>
TITLE: ***Human*** respiratory syncytial virus peptides with antifusogenic and antiviral activities
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228983	B1	20010508
APPLICATION INFO.:	US 1995-485264		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.

LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 32166
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a ***human*** respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTIS, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:95093 USPATFULL <<LOGINID::20080424>>
TITLE: Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6093794		20000725
APPLICATION INFO.:	US 1995-471913		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 19949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of ***human*** and non- ***human*** retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:67564 USPATFULL <<LOGINID::20080424>>
TITLE: Methods for inhibition of membrane fusion-associated events, including influenza virus
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6068973		20000530

APPLICATION INFO.: US 1995-485551 19950607 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Park, Hankyel
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 12021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1 sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of ***human*** and non- ***human*** retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:57361 USPATFULL <<LOGINID::20080424>>
TITLE: Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)
Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060065		20000509
APPLICATION INFO.:	US 1995-475668		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Parley, Hankyel T.
LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 19987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to viral peptides referred to as "DP107- and DP178-like" peptides. Specifically, the invention relates to isolated influenza A DP107- and DP178-like peptides which are identified by sequence search motif algorithms. The peptides of the invention exhibit antiviral activity believed to result from inhibition of viral induced fusogenic events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:50515 USPATFULL <<LOGINID::20080424>>
TITLE: Screening assays for compounds that inhibit membrane fusion-associated events
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Jr., Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054265		20000425
APPLICATION INFO.:	US 1997-919597		19970926 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 83 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 21307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of ***human*** and non- ***human*** retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:12922 USPATFULL <<LOGINID::20080424>>
TITLE: Isolated peptides derived from ***human*** immunodeficiency virus types 1 and 2 containing fusion inhibitory domains
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020459		20000201
APPLICATION INFO.:	US 1995-484223		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 75
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)

LINE COUNT: 20335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of ***human*** and non- ***human*** retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:9527 USPATFULL <<LOGINID::20080424>>
TITLE: Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
INVENTOR(S): Barney, Shawn OLin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
Langlois, Alphonse J., Durham, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017536		20000125
APPLICATION INFO.:	US 1994-360107		19941220 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 50 Drawing Figure(s); 62 Drawing Page(s)
LINE COUNT: 20227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTIS, 107.times.178.times.4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:4427 USPATFULL <<LOGINID::20080424>>
TITLE: Measles virus peptides with antifusogenic and antiviral activities
INVENTOR(S): Barney, Shawn OLin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013263		20000111
APPLICATION INFO.:	US 1995-486099		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 Ser. No. Ser. No. US 1994-255208, filed on 7 Jun 1994 And Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No.

US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 19827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of ***human*** and non- ***human*** retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> D his

L1 QUE ((TETRAHYDROFOLATE (W) SYNTHASE) OR (TETRAHYDROFOLATE (W) S

L2 670 S L1
L3 35 S (CANCER OR CARCINOMA OR TUMOR OR NEOPLASIA) (S) L2
L4 27 S (COLON OR COLORECTAL) AND L3
L5 25 S EXPRESS? AND L4
L6 23 S (DETECT? OR DIAGNOS?) AND L5
L7 23 S HUMAN AND L6
L8 23 DUP REM L7 (0 DUPLICATES REMOVED)

=> log Y